• 1. Department of Gastrointestinal Surgery & Laboratory of Gastric Cancer, West China Hospital, Sichuan University, Chengdu 610041,P. R. China;
  • 2. Department of General Surgery, West China Longquan Hospital, Sichuan University, Chengdu 610100, P. R. China;
CHEN Xinzu, Email: chenxinzu@scu.edu.cn
Export PDF Favorites Scan Get Citation

Objectives To summarize the latest advances about definition, classification, and TNM stage of adenocarcinoma of esophagogastric junction (AEG).Method The available guidelines, consensuses, international conference proceedings, and clinical studies were reviewed and summarized.Results The AEG trended to be an independent entity of malignant tumor at the special location. The previous misunderstanding of AEG definitions from the WHO needed to be corrected and unified in China. The Siewert classification was still a practical clinical approach to guiding treatment strategy, while the new draft of JGCA classification needed to be evaluated and verified in the clinical practice. By contrast, the 8th edition AJCC/UICC classification was relatively controversial in the guiding treatment strategies, mainly due to the staging system, surgical approach, and extent of lymphadenectomy of Siewert Ⅱ type AEG. Based on the available research results, the TNM staging system of the 8th edition of gastric cancer tended to be more reasonable for the Siewert Ⅱ and Ⅲ types AEG.Conclusion With increasing incidence of AEG, more experimental and clinical studies on AEG are ongoing, and it is expected to have more optimized classification and exclusive staging system for AEG in future.

Citation: LIU Kai, ZHANG Weihan, CHEN Xinzu. Definition, classification, and staging for adenocarcinoma of esophagogastric junction: updates in controversies. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2019, 26(9): 1040-1045. doi: 10.7507/1007-9424.201907029 Copy

  • Previous Article

    MDT 在食管胃结合部腺癌治疗中的作用
  • Next Article

    Comparison between indocyanine green fluorescence imaging plus methylene blue and radioactive nuclide plus methylene blue for sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer patients